Bolt Biotherapeutics, Inc. — Form 8-K
Filed August 11, 2026 · analyzed by the 8-K Agent
8-K
▼ Likely negative
significance 78/100
What the filing says
Bolt Biotherapeutics reported Q2 2026 net loss of $7.7M (vs. $8.6M in Q2 2025) on collaboration revenue of $5K (vs. $1.8M prior year). Cash and equivalents totaled $18.1M as of June 30, 2026, expected to fund operations into Q1 2027. Lead program BDC-4182 Phase 1/2 trial progresses in Cohort 4 (4.0 mg/kg dose); initial clinical data expected with Q3 2026 results. R&D expenses declined to $5.1M from $7.5M YoY following restructuring.
Why this rating
Critical cash runway shortfall (9 months at current burn) and steep collaboration revenue drop signal existential pressure for $7.3M market cap company. Lead asset on track but funding cliff imminent.
See more from August 11, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.